Spero Therapeutics, Inc. financial data

Symbol
SPRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
675 Massachusetts Avenue, 14 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Spero Therapeutics, LLC (to 3/21/2017)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 270 % -34.4%
Debt-to-equity 95.3 % +21%
Return On Assets 11.5 %
Operating Margin -153 % -839%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.9M shares +3.77%
Common Stock, Shares, Outstanding 54.6M shares +3.01%
Entity Public Float 69.5M USD -8.55%
Common Stock, Value, Issued 55K USD +3.77%
Weighted Average Number of Shares Outstanding, Basic 54M shares +2.53%
Weighted Average Number of Shares Outstanding, Diluted 54M shares +1.98%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 48M USD -53.8%
Revenue from Contract with Customer, Excluding Assessed Tax 371K USD -60.2%
Research and Development Expense 96.8M USD +88.1%
General and Administrative Expense 23.7M USD -7.24%
Operating Income (Loss) -73.4M USD -442%
Nonoperating Income (Expense) 4.8M USD +22.2%
Income Tax Expense (Benefit) -290K USD -113%
Net Income (Loss) Attributable to Parent 17.4M USD -50.4%
Earnings Per Share, Basic -1.27 USD/shares -395%
Earnings Per Share, Diluted -1.27 USD/shares -395%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.9M USD -30.7%
Assets, Current 107M USD -18.2%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 3.11M USD -25.1%
Other Assets, Noncurrent 153K USD -64.8%
Assets 111M USD -39.4%
Accounts Payable, Current 7.31M USD +430%
Employee-related Liabilities, Current 5.46M USD +63.4%
Liabilities, Current 49.1M USD +32.1%
Operating Lease, Liability, Noncurrent 2.55M USD -33.3%
Liabilities 64.4M USD -14.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -460M USD -17.5%
Stockholders' Equity Attributable to Parent 46.1M USD -56.9%
Liabilities and Equity 111M USD -39.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 5.94M USD
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54.6M shares +3.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.94M USD
Deferred Tax Assets, Valuation Allowance 122M USD +13.3%
Deferred Tax Assets, Gross 122M USD +13.3%
Operating Lease, Liability 4.3M USD -22.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 22.8M USD +91.2%
Lessee, Operating Lease, Liability, to be Paid 4.86M USD -26.1%
Property, Plant and Equipment, Gross 3.62M USD 0%
Operating Lease, Liability, Current 1.75M USD +1.63%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.96M USD +13.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 561K USD -45.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.16M USD -33.8%
Deferred Tax Assets, Operating Loss Carryforwards 42.3M USD +65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.96M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%